• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Clinical Value of Autoantibody Prognostic Markers in Tumor Immune Checkpoint 
Inhibitor Therapy].[自身抗体预后标志物在肿瘤免疫检查点抑制剂治疗中的临床价值]
Zhongguo Fei Ai Za Zhi. 2022 Jul 20;25(7):534-540. doi: 10.3779/j.issn.1009-3419.2022.101.28.
2
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.与免疫检查点抑制剂相关的极重度免疫相关不良事件的决定因素：法国 REISAMIC 注册前瞻性研究。
Eur J Cancer. 2021 Nov;158:217-224. doi: 10.1016/j.ejca.2021.08.048. Epub 2021 Oct 7.
3
Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.癌症患者接受免疫检查点抑制剂治疗的特定免疫相关不良事件的真实世界临床和经济结局。
Oncologist. 2021 Nov;26(11):e2002-e2012. doi: 10.1002/onco.13918. Epub 2021 Aug 24.
4
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.免疫相关不良事件与免疫检查点抑制剂在有食品和药物管理局批准的免疫治疗适应证的胃肠道癌患者中的疗效。
Oncologist. 2020 Aug;25(8):669-679. doi: 10.1634/theoncologist.2019-0637. Epub 2020 Jan 14.
5
Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines.预测和预防免疫检查点抑制剂毒性：靶向细胞因子。
Trends Immunol. 2021 Apr;42(4):293-311. doi: 10.1016/j.it.2021.02.006. Epub 2021 Mar 10.
6
and predict immune-related adverse events and efficacy of immune checkpoint inhibitor.并预测免疫相关不良事件和免疫检查点抑制剂的疗效。
Front Immunol. 2023 May 3;14:1164724. doi: 10.3389/fimmu.2023.1164724. eCollection 2023.
7
Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study.免疫检查点抑制剂引起的垂体功能减退与恶性黑色素瘤和非小细胞肺癌的总生存改善相关：一项前瞻性研究。
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000779.
8
Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.免疫相关不良反应与免疫检查点抑制剂疗效和获益的关系：系统评价和荟萃分析。
Cancer Treat Rev. 2021 Jan;92:102134. doi: 10.1016/j.ctrv.2020.102134. Epub 2020 Dec 3.
9
Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence.基于临床和血液学指标预测接受免疫检查点抑制剂治疗的非小细胞肺癌患者的免疫相关不良事件：真实世界证据
Exp Cell Res. 2022 Jul 1;416(1):113157. doi: 10.1016/j.yexcr.2022.113157. Epub 2022 Apr 12.
10
Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.癌症患者因出现 ≥2 级免疫相关不良反应而停止使用免疫检查点抑制剂后再次使用的安全性。
J Immunother Cancer. 2020 Dec;8(2). doi: 10.1136/jitc-2020-001622.

本文引用的文献

1
Tumour- associated autoantibodies as prognostic cancer biomarkers- a review.肿瘤相关自身抗体作为预后癌症生物标志物的研究进展。
Autoimmun Rev. 2022 Apr;21(4):103041. doi: 10.1016/j.autrev.2022.103041. Epub 2022 Jan 12.
2
Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies.纳武利尤单抗诱导的免疫相关不良事件与一系列自身抗体相关。
Ann Med. 2021 Dec;53(1):762-769. doi: 10.1080/07853890.2021.1931956.
3
Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung Cancer.针对肿瘤相关抗原的外周血自身抗体可预测晚期非小细胞肺癌基于免疫检查点抑制剂治疗的临床结局
Front Oncol. 2021 Mar 16;11:625578. doi: 10.3389/fonc.2021.625578. eCollection 2021.
4
LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome.LRPAP1 自身抗体在套细胞淋巴瘤中与较好的预后相关。
Blood. 2021 Jun 10;137(23):3251-3258. doi: 10.1182/blood.2020008835.
5
Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.循环肿瘤相关自身抗体与接受 PD-1/-L1 靶向免疫检查点抑制的晚期 NSCLC 患者临床结局的关系。
J Immunol Methods. 2021 Mar;490:112956. doi: 10.1016/j.jim.2021.112956. Epub 2021 Jan 9.
6
IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137T-cells.IgM 型类风湿因子通过减少 CD137T 细胞赋予 NSCLC 患者对 PD-1 免疫治疗的原发性耐药性。
EBioMedicine. 2020 Dec;62:103098. doi: 10.1016/j.ebiom.2020.103098. Epub 2020 Nov 6.
7
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.帕博利珠单抗治疗的晚期实体瘤患者肿瘤突变负荷与结局的相关性：多队列、开放标签、Ⅱ期 KEYNOTE-158 研究的前瞻性生物标志物分析。
Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.
8
[Expert consensus on PD-L1 expression testing in non-small-cell lung cancer in China].《中国非小细胞肺癌PD-L1表达检测专家共识》
Zhonghua Zhong Liu Za Zhi. 2020 Jul 23;42(7):513-521. doi: 10.3760/cma.j.cn112152-20200313-00202.
9
Stem signatures associated antibodies yield early diagnosis and precise prognosis predication of patients with non-small cell lung cancer.与干细胞特征相关的抗体能够为非小细胞肺癌患者提供早期诊断和精确的预后预测。
J Cancer Res Clin Oncol. 2021 Jan;147(1):223-233. doi: 10.1007/s00432-020-03325-4. Epub 2020 Jul 20.
10
Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients.自身抗体谱分析鉴定出癌症患者对 PD-1 治疗反应的预测性生物标志物。
Theranostics. 2020 May 16;10(14):6399-6410. doi: 10.7150/thno.45816. eCollection 2020.

[自身抗体预后标志物在肿瘤免疫检查点抑制剂治疗中的临床价值]

[Clinical Value of Autoantibody Prognostic Markers in Tumor Immune Checkpoint 
Inhibitor Therapy].

作者信息

Dai Liyuan, Han Xiaohong

机构信息

Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, 
Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.

Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.

出版信息

Zhongguo Fei Ai Za Zhi. 2022 Jul 20;25(7):534-540. doi: 10.3779/j.issn.1009-3419.2022.101.28.

DOI:10.3779/j.issn.1009-3419.2022.101.28
PMID:35899453
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9346161/
Abstract

Serum autoantibody markers have the advantages of easy specimen acquisition, simple detection technology and dynamic real-time monitoring. With the wide application of immune checkpoint inhibitors in the treatment of malignant tumors, autoantibody markers in predicting tumor immune checkpoint inhibitors efficacy and forecasting irAEs (immune related adverse events) show good prediction of potential. This review mainly focused on the progress of autoantibody markers in the prediction of therapeutic effect and the monitoring of irAE in tumor immunotherapy.
.

摘要

血清自身抗体标志物具有标本采集简便、检测技术简单以及动态实时监测等优点。随着免疫检查点抑制剂在恶性肿瘤治疗中的广泛应用，自身抗体标志物在预测肿瘤免疫检查点抑制剂疗效及预测免疫相关不良事件（irAEs）方面显示出良好的预测潜力。本综述主要聚焦于自身抗体标志物在肿瘤免疫治疗中疗效预测及irAE监测方面的进展。